As of Mar 22
| -0.105 / -3.39%|
The 4 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 5.00, with a high estimate of 6.00 and a low estimate of 4.50. The median estimate represents a +66.94% increase from the last price of 3.00.
The current consensus among 4 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.